Physician profile
Thy A Lam
NPI 1083277255
$121,095.76
in general payments reported to CMS, 2019-2025
17 companies · $70K in 2025
The $70K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $998 · 2022: $4,362 · 2023: $16K · 2024: $29K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Food and Beverage: $24K · Travel and Lodging: $14K · Consulting Fee: $1,238 · Education: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,267.00 |
| Food and Beverage | $24,241.42 |
| Travel and Lodging | $14,329.62 |
| Consulting Fee | $1,238.00 |
| Education | $659.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $92,811.34 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Indivior INC. | $5,159.48 | 2021-2024 | Perseris |
| Alkermes, INC. | $3,561.04 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $3,421.97 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $3,020.73 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $2,727.24 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $2,212.61 | 2021-2025 | Invega Sustenna, Invega, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,154.13 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,096.53 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $1,624.40 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $716.36 | 2022-2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $470.06 | 2022-2025 | Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $466.45 | 2021-2022 | |
| Axsome Therapeutics, INC. | $344.55 | 2023-2024 | Auvelity |
| Tempus Ai, INC | $200.55 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $64.51 | 2023 | Nuplazid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thy Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.